The Innovative Fixed-Dose Combination Will Help Improving The Glycemic ControlAmong Adult Patients With Insulin Resistance, Those Whose Diabetes Is UncontrolledBy Metformin; And Also Those Who Require Addition Of Teneliglitptin AndPioglitazone As Separate Drugs. Launched Under The Brand Name Zita Plus Pio, TheDrug Will Increase The Accessibility Of Quality Drug For Effective DiabetesManagement.Glenmark PharmaceuticalsLimited (Glenmark), AnInnovation-Driven GlobalPharmaceutical Company HasLaunched A Novel Fixed-DoseCombination (Fdc) Of A WidelyUsed Dpp4 Inhibitor (DipeptidylPeptidase 4 Inhibitor),Teneligliptin, With Pioglitazone. This Is The Only Available Dpp4 And Glitazone Combination Brand In India For Adults With Uncontrolled Type 2 Diabetes. GlenmarkHas Launched This Fdc Under The Brand Name Zita Plus Pio, Which ContainsTeneligliptin (20 Mg) + Pioglitazone (15 Mg), To Be Taken Once A Day.Commenting On The Development, Alok Malik, Group Vice President & Head, IndiaFormulations
